ChemBioBridge - Bridging chemical and biological experimental design for pharma industry through data fusion.
From 01-07-2014 to 30-06-2016
Description
In the different therapeutic areas of drug development, the growing dimensionality in chemical space and biological data (multi-target, multi-gene, multi-pathway) is highly challenging and will become an important bottleneck in the future decision making process. Therefore, it is critical to improve the fusion of disease mechanisms and disease phenotypes with the corresponding biological and medicinal chemistry decision cascades.
The general aim of this project is to span the high-dimensional biological and compound space by ensuring that the different effect levels are fused (Disease ,Gene set, Gene ranking, Protein target ranking, Compound ranking) with all available or specifically new experimental data. By solving the data fusion challenges of all those data types, we aim to improve the efficiency of phenotypic drug design (and diminish the explosion of follow-up costs).
The final result will be a small number of potential biological or chemical hypotheses, that project teams can rely on and that are small enough to allow cost-efficient follow-up scenarios, either at the protein target identification or chemical probinglevel (hit enrichment).
Team
- Sepp Hochreiter, Co-promoter (External)
- Yves Moreau, Co-promoter
- Joerg Kurt Wegner, Promoter (External)
- Inge Thijs, Team member
- Griet Laenen, Team member
- Ádám Arany, Team member
- Hugo Ceulemans, Team member (External)
Financing
Funding: IWT - Agentschap voor Innovatie door Wetenschap en Technologie
Program/Grant Type: IWT O&O - IWT Industrial R&D projects
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.